A Phase 1/2, open-label, single-arm, dose-escalation and dose-expansion study of the safety, tolerability, pharmacokinetic, and antitumor activity of E-602 as a single agent and in combination with pembrolizumab in patients with advanced cancers
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to test the safety of the study drug, E-602, at different dose levels both alone (monotherapy) and in combination with pembrolizumab (also known as Keytruda). Pembrolizumab is FDA-approved for the treatment of some cancers, but not all of the cancers in this study. E-602 has not been approved by the United States Food and Drug Administration (FDA). This study is the first time that E-602 will be administered to participants. The study will also inform on what effects, both good and bad, E-602 alone and in combination with pembrolizumab have on participants with advanced cancer. Cancers include: breast cancer, colon and rectal cancer, esophageal cancer, head and neck/oral cancer, lung cancer, melanoma, pancreatic cancer, and ovarian cancer.
Brian Henick, MD
|Are you at least 18 years old?
|Have you been diagnosed with advanced cancer?